Dartmouth Health Continuing Education for Professionals Home, Nonalcoholic Fatty Liver Disease, 4/21/2022 8:00:00 AM - 4/21/2025 9:00:00 AM,
Presenter
Mary Drinane, MD
Department of Gastroenterology & Hepalology
Dartmouth Hitchcock Health
Learning Outcome(s)
Learners will be able to apply current clinical research and principles of evidence-based medicine to determine clinical diagnoses by formulating and implementing acceptable treatment modalities for Nonalcoholic Fatty Liver Disease.
Disclosure
The activity director(s), planning committee member(s), speaker(s), author(s) or anyone in a position to control the content for this activity have reported NO financial relationship(s)* with ineligible companies**.
* A “financial relationship" includes employee, researcher (named as the PI), consultant, advisor, speaker, independent contractor (including contracted research), royalties or patent beneficiary, executive role, and/or an ownership interest (not including stocks owned in a managed portfolio).
** An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Bibliographic Material
See presentation for bibliographic sources to allow for further study.
Presenter
Mary Drinane, MD
Department of Gastroenterology & Hepalology
Dartmouth Hitchcock Health
Learning Outcome(s)
Learners will be able to apply current clinical research and principles of evidence-based medicine to determine clinical diagnoses by formulating and implementing acceptable treatment modalities for Nonalcoholic Fatty Liver Disease.
Disclosure
The activity director(s), planning committee member(s), speaker(s), author(s) or anyone in a position to control the content for this activity have reported NO financial relationship(s)* with ineligible companies**.
* A “financial relationship" includes employee, researcher (named as the PI), consultant, advisor, speaker, independent contractor (including contracted research), royalties or patent beneficiary, executive role, and/or an ownership interest (not including stocks owned in a managed portfolio).
** An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Bibliographic Material
See presentation for bibliographic sources to allow for further study.
